BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M; WHO Paediatric Antiretroviral Working Group. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol 2018;11:83-93. [PMID: 29039686 DOI: 10.1080/17512433.2018.1393331] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chiappini E, Lisi C, Giacomet V, Erba P, Bernardi S, Zangari P, Di Biagio A, Taramasso L, Giaquinto C, Rampon O, Gabiano C, Garazzino S, Tagliabue C, Esposito S, Bruzzese E, Badolato R, Zanaboni D, Cellini M, Dedoni M, Mazza A, Pession A, Giannini AM, Salvini F, Dodi I, Carloni I, Cazzato S, Tovo PA, de Martino M, Galli L; Italian Register for HIV Infection in Children. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children. BMC Infect Dis 2022;22:55. [PMID: 35033018 DOI: 10.1186/s12879-022-07026-w] [Reference Citation Analysis]
2 Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P; IMPAACT 2007 Study Team. Pharmacokinetics and safety of maraviroc in neonates. AIDS 2021;35:419-27. [PMID: 33252481 DOI: 10.1097/QAD.0000000000002762] [Reference Citation Analysis]
3 Gratton R, Tricarico PM, Guimaraes RL, Celsi F, Crovella S. Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line. CHR 2018;16:106-12. [DOI: 10.2174/1570162x16666180528100922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Dirajlal-Fargo S, Koay WLA, Rakhmanina N. Pediatric Antiretroviral Therapy. Handb Exp Pharmacol 2020;261:285-323. [PMID: 31286213 DOI: 10.1007/164_2019_246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Anugulruengkitt S, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, Punnahitanon S, Pancharoen C, Cressey TR, Chokephaibulkit K, Puthanakit T; CIPHER_AEPEP study team. Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. Pediatr Infect Dis J 2019;38:1045-50. [PMID: 31365477 DOI: 10.1097/INF.0000000000002426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Archary M, Zanoni B, Lallemant M, Suwannaprom P, Clarke D, Penazzato M. Acceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource Setting. Pediatr Infect Dis J 2020;39:57-60. [PMID: 31815839 DOI: 10.1097/INF.0000000000002539] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kuhn L, Strehlau R, Shiau S, Patel F, Shen Y, Technau KG, Burke M, Sherman G, Coovadia A, Aldrovandi GM, Hazra R, Tsai WY, Tiemessen CT, Abrams EJ; LEOPARD Study Team. Early antiretroviral treatment of infants to attain HIV remission. EClinicalMedicine 2020;18:100241. [PMID: 31993578 DOI: 10.1016/j.eclinm.2019.100241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
8 Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother 2020;75:640-7. [PMID: 31860112 DOI: 10.1093/jac/dkz506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Abrams EJ, Ananworanich J, Archary M, Ngongondo M, Brouwers P. Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration. J Acquir Immune Defic Syndr 2018;78 Suppl 1:S32-9. [PMID: 29994918 DOI: 10.1097/QAI.0000000000001747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
10 Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV 2019;6:e623-31. [PMID: 31498110 DOI: 10.1016/S2352-3018(19)30193-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Malati CY, Golin R, O'Brien L, Sugandhi N, Srivastava M, Larson C, Phelps BR. Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules. J Int AIDS Soc 2019;22:e25267. [PMID: 30983152 DOI: 10.1002/jia2.25267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]